# CLDN6

## Overview
The CLDN6 gene encodes claudin 6, a tetraspan transmembrane protein that is a critical component of tight junctions in epithelial and endothelial cells. Claudin 6 is involved in maintaining cell polarity and regulating paracellular transport, which is essential for the selective permeability of epithelial barriers (Du2021Claudin; Zhang2021Identification). The protein's structure, characterized by four transmembrane domains and two extracellular loops, facilitates its role in cell-cell adhesion and barrier function (Sugimoto2021The). Claudin 6 is implicated in various physiological processes, including epithelial differentiation and organogenesis, particularly in lung development (Jimenez2014Developmental). Additionally, CLDN6 has been associated with cancer progression, where its expression levels and interactions with other proteins can influence tumor growth and metastasis, highlighting its dual role as both a tumor suppressor and promoter depending on the context (Kojima2021Aberrant; Qu2021CLDN6).

## Structure
Claudin 6 (CLDN6) is a tetraspan transmembrane protein, consisting of four transmembrane domains that are integral to its function in tight junctions within epithelial and endothelial cells (Du2021Claudin; Zhang2021Identification). The protein is composed of 220 amino acids and has a molecular mass of approximately 23 kDa (Zhang2021Identification). The structure includes two extracellular loops, which are crucial for cell-cell adhesion and paracellular barrier functions (Sugimoto2021The). The first extracellular loop (EC1) is particularly involved in forming paracellular barriers or pores for selective ions and solutes (Sugimoto2021The).

The C-terminal cytoplasmic domain of CLDN6 contains a PDZ-binding motif, which is important for intracellular signaling and interactions with cytoskeletal proteins (Du2021Claudin). This domain also includes conserved tyrosine residues, Y196 and Y200, which are phosphorylated and play a role in signaling pathways involving Src-family kinases (SFKs) and the PI3K/AKT pathway (Sugimoto2021The). These post-translational modifications are essential for the protein's role in signal transduction and cellular responses (Sugimoto2021The). The specific arrangement of these domains and motifs contributes to the protein's ability to regulate tight junction dynamics and cellular adhesion.

## Function
Claudin 6 (CLDN6) is a transmembrane protein that plays a crucial role in the formation and maintenance of tight junctions in epithelial cells. These tight junctions are essential for maintaining cell polarity and regulating paracellular transport, which is the movement of substances between cells. CLDN6 is involved in epithelial differentiation, as demonstrated in studies using mouse F9 stem cells, where its expression led to the formation of tight-junction strands and microvilli, structures important for apicobasal cell polarity (Sugimoto2013The). 

In the context of lung development, CLDN6 is expressed during early stages of organogenesis and is co-expressed with transcription factors such as TTF-1, FoxA2, and Gata-6, which are important for lung branching morphogenesis and cell differentiation (Jimenez2014Developmental). The expression of CLDN6 peaks at embryonic day 12.5 and decreases as lung development progresses, indicating its role in early lung epithelial cell differentiation and the maintenance of membrane permeability (Jimenez2014Developmental). 

Although CLDN6-null mice do not exhibit abnormalities, suggesting possible compensation by other claudins, CLDN6 is considered pivotal for epithelial morphogenesis and differentiation from stem cells to various embryonal epithelia (Sugimoto2013The).

## Clinical Significance
Alterations in the expression of the CLDN6 gene have been implicated in various cancers, including breast, endometrial, gastric, and hepatocellular carcinoma. In breast cancer, CLDN6 is typically expressed at lower levels in cancerous tissues compared to non-neoplastic tissues, and its low expression is associated with poor prognosis. Overexpression of CLDN6 in breast cancer cells inhibits proliferation by suppressing c-MYC-mediated aerobic glycolysis, which is crucial for cancer cell proliferation (Qu2021CLDN6). CLDN6 also plays a role in inhibiting breast cancer metastasis by interacting with β-catenin and reducing HIF-1α stability, thereby mitigating hypoxia-induced metastasis (Jia2020A).

In endometrial cancer, high CLDN6 expression is associated with increased cellular proliferation, migration, and tumor growth. It activates Src family kinases, promoting cancer progression through the PI3K/AKT/mTOR pathway (Kojima2021Aberrant). In gastric cancer, CLDN6 affects the YAP1 and YAP1-Snail axes, promoting proliferation and invasion (Du2021Claudin). In hepatocellular carcinoma, CLDN6 is highly expressed and promotes EMT and proliferation through the EGFR/AKT/mTOR pathway (Du2021Claudin). These findings suggest that CLDN6 plays a complex role in cancer development and progression, acting as a tumor suppressor in some contexts and a promoter in others.

## Interactions
CLDN6 interacts with various proteins, influencing cancer progression and cell signaling. In breast cancer, CLDN6 is involved in an anti-metastatic role by interacting with β-catenin. This interaction occurs in the cytoplasm, where CLDN6 binds to β-catenin, preventing its nuclear translocation and promoting its degradation via the ubiquitin pathway. This process downregulates SENP1 expression, which is part of the SENP1/HIF-1α signaling pathway (Jia2020A).

In endometrial cancer, CLDN6 interacts with Src-family kinases (SFKs), particularly phosphorylated SFKs, at cell boundaries. This interaction is crucial for promoting cancer progression and is dependent on the second extracellular domain and specific tyrosine residues (Y196/200) of CLDN6 (Kojima2021Aberrant).

In gastric cancer cells, CLDN6 enhances cell invasiveness through its interaction with claudin-1. This interaction leads to increased activity of matrix metalloproteinases (MMPs), specifically MMP-2 and MMP-14, which are associated with enhanced cell migration and invasiveness (TorresMartínez2017Claudin6).

CLDN6 also interacts with members of the Src-family kinases, such as BLK and SRC, at mature cell-cell junctions. This interaction is dependent on the C-terminal cytoplasmic domain of CLDN6 (IchikawaTomikawa2023The).


## References


[1. (Jimenez2014Developmental) Felix R Jimenez, Joshua B Lewis, Samuel T Belgique, Tyler T Wood, and Paul R Reynolds. Developmental lung expression and transcriptional regulation of claudin-6 by ttf-1, gata-6, and foxa2. Respiratory Research, June 2014. URL: http://dx.doi.org/10.1186/1465-9921-15-70, doi:10.1186/1465-9921-15-70. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/1465-9921-15-70)

[2. (Sugimoto2013The) Kotaro Sugimoto, Naoki Ichikawa-Tomikawa, Seiro Satohisa, Yushi Akashi, Risa Kanai, Tsuyoshi Saito, Norimasa Sawada, and Hideki Chiba. The tight-junction protein claudin-6 induces epithelial differentiation from mouse f9 and embryonic stem cells. PLoS ONE, 8(10):e75106, October 2013. URL: http://dx.doi.org/10.1371/journal.pone.0075106, doi:10.1371/journal.pone.0075106. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0075106)

[3. (Sugimoto2021The) Kotaro Sugimoto and Hideki Chiba. The claudin–transcription factor signaling pathway. Tissue Barriers, April 2021. URL: http://dx.doi.org/10.1080/21688370.2021.1908109, doi:10.1080/21688370.2021.1908109. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/21688370.2021.1908109)

[4. (Qu2021CLDN6) Huinan Qu, Da Qi, Xinqi Wang, Yuan Dong, Qiu Jin, Junyuan Wei, and Chengshi Quan. Cldn6 suppresses c–myc–mediated aerobic glycolysis to inhibit proliferation by taz in breast cancer. International Journal of Molecular Sciences, 23(1):129, December 2021. URL: http://dx.doi.org/10.3390/ijms23010129, doi:10.3390/ijms23010129. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23010129)

[5. (Zhang2021Identification) Chiyuan Zhang, Cuishan Guo, Yan Li, Kuiran Liu, Qi Zhao, and Ling Ouyang. Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Frontiers in Cell and Developmental Biology, August 2021. URL: http://dx.doi.org/10.3389/fcell.2021.726656, doi:10.3389/fcell.2021.726656. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.726656)

[6. (IchikawaTomikawa2023The) Naoki Ichikawa-Tomikawa, Kotaro Sugimoto, Korehito Kashiwagi, and Hideki Chiba. The src-family kinases src and blk contribute to the cldn6-adhesion signaling. Cells, 12(13):1696, June 2023. URL: http://dx.doi.org/10.3390/cells12131696, doi:10.3390/cells12131696. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12131696)

[7. (Kojima2021Aberrant) Manabu Kojima, Kotaro Sugimoto, Makoto Kobayashi, Naoki Ichikawa-Tomikawa, Korehito Kashiwagi, Takafumi Watanabe, Shu Soeda, Keiya Fujimori, and Hideki Chiba. Aberrant claudin-6–adhesion signaling promotes endometrial cancer progression via estrogen receptor α. Molecular Cancer Research, 19(7):1208–1220, March 2021. URL: http://dx.doi.org/10.1158/1541-7786.mcr-20-0835, doi:10.1158/1541-7786.mcr-20-0835. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1158/1541-7786.mcr-20-0835)

[8. (TorresMartínez2017Claudin6) A.C. Torres-Martínez, J.F. Gallardo-Vera, A.N. Lara-Holguin, L.F. Montaño, and E.P. Rendón-Huerta. Claudin-6 enhances cell invasiveness through claudin-1 in ags human adenocarcinoma gastric cancer cells. Experimental Cell Research, 350(1):226–235, January 2017. URL: http://dx.doi.org/10.1016/j.yexcr.2016.11.025, doi:10.1016/j.yexcr.2016.11.025. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2016.11.025)

[9. (Du2021Claudin) Huan Du, Xiyue Yang, Jinjia Fan, and Xiaobo Du. Claudin 6: therapeutic prospects for tumours, and mechanisms of expression and regulation (review). Molecular Medicine Reports, July 2021. URL: http://dx.doi.org/10.3892/mmr.2021.12316, doi:10.3892/mmr.2021.12316. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2021.12316)

[10. (Jia2020A) Yiyang Jia, Yantong Guo, Qiu Jin, Huinan Qu, Da Qi, Peiye Song, Xiaoli Zhang, Xinqi Wang, Wenhong Xu, Yuan Dong, Yingying Liang, and Chengshi Quan. A sumoylation-dependent hif-1α/cldn6 negative feedback mitigates hypoxia-induced breast cancer metastasis. Journal of Experimental &amp; Clinical Cancer Research, February 2020. URL: http://dx.doi.org/10.1186/s13046-020-01547-5, doi:10.1186/s13046-020-01547-5. This article has 30 citations.](https://doi.org/10.1186/s13046-020-01547-5)